Get the Stockscreener App
5.48
2.81%
0.15
Dermata Therapeutics Inc stock is traded at $5.48, with a volume of 13,065.
It is up +2.81% in the last 24 hours and down -21.38% over the past month.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
See More
Previous Close:
$5.33
Open:
$5.475
24h Volume:
13,065
Relative Volume:
0.81
Market Cap:
$3.73M
Revenue:
-
Net Income/Loss:
$-11.27M
P/E Ratio:
-0.2559
EPS:
-21.4132
Net Cash Flow:
$-9.40M
1W Performance:
-8.36%
1M Performance:
-21.38%
6M Performance:
-56.16%
1Y Performance:
-70.22%
1-Day Range:
$5.30
$5.605
1-Week Range:
$5.09
$6.092
52-Week Range:
$5.09
$24.90
Dermata Therapeutics Inc Stock (DRMA) Company Profile
Name
Dermata Therapeutics Inc
Sector
Industry
Phone
(858)-223-0882
Address
3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO
Compare DRMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRMA
Dermata Therapeutics Inc
|
5.48 | 3.78M | 0 | -11.27M | -9.40M | -21.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Dermata Therapeutics Inc Stock (DRMA) Latest News
What high frequency data says about Dermata Therapeutics Inc. Equity Warrant2025 Price Targets & Verified Chart Pattern Trade Signals - Newser
Will Dermata Therapeutics Inc. continue its uptrend2025 AllTime Highs & Technical Confirmation Alerts - Newser
Dermata Therapeutics Inc. Equity Warrant stock volume spike explained2025 Support & Resistance & Low Risk Entry Point Guides - Newser
What candlestick patterns are forming on Dermata Therapeutics Inc.CEO Change & High Return Trade Opportunity Guides - Newser
Is Dermata Therapeutics Inc. Equity Warrant a candidate for recovery playMarket Growth Summary & Free Low Drawdown Momentum Trade Ideas - Newser
Is a relief rally coming for Dermata Therapeutics Inc. Equity Warrant holdersEarnings Risk Summary & Community Verified Watchlist Alerts - Newser
Price action breakdown for Dermata Therapeutics Inc.Long Setup & Stepwise Entry and Exit Trade Signals - Newser
Understanding Dermata Therapeutics Inc.’s price movementJuly 2025 Catalysts & Weekly Chart Analysis and Guides - Newser
Full technical analysis of Dermata Therapeutics Inc. Equity Warrant stockJuly 2025 PreEarnings & Reliable Breakout Stock Forecasts - Newser
Should you wait for a breakout in Dermata Therapeutics Inc. Equity WarrantMarket Performance Recap & Fast Gaining Stock Strategy Reports - Newser
Dermata Therapeutics Inc. Equity Warrant recovery potential after sell offWeekly Market Report & Weekly High Momentum Picks - Newser
Smart tools for monitoring Dermata Therapeutics Inc. Equity Warrant’s price actionJuly 2025 Big Picture & AI Enhanced Trading Alerts - Newser
How to integrate Dermata Therapeutics Inc. Equity Warrant into portfolio analysis tools2025 Fundamental Recap & AI Based Buy and Sell Signals - Newser
Predicting Dermata Therapeutics Inc. Equity Warrant trend using moving averagesJuly 2025 Pullbacks & Low Drawdown Momentum Ideas - Newser
How high can Dermata Therapeutics Inc. stock goTreasury Yields & Proven Capital Preservation Tips - Newser
Can machine learning forecast Dermata Therapeutics Inc. recoveryJuly 2025 Intraday Action & Free Fast Gain Swing Trade Alerts - Newser
Sentiment analysis tools applied to Dermata Therapeutics Inc.2025 Fundamental Recap & Daily Stock Momentum Reports - Newser
Identifying reversal signals in Dermata Therapeutics Inc.Rate Cut & Verified Momentum Watchlists - Newser
Will Dermata Therapeutics Inc. stock benefit from AI tech trendsEarnings Trend Report & Growth Focused Stock Reports - Newser
What machine learning models say about Dermata Therapeutics Inc. Equity WarrantMarket Risk Report & Pattern Based Trade Signal System - Newser
Statistical indicators supporting Aeva Technologies Inc.’s strength2025 EndofYear Setup & Community Consensus Stock Picks - Newser
Is Dermata Therapeutics Inc. forming a bottoming baseCEO Change & Verified Technical Signals - Newser
Is Dermata Therapeutics Inc. Equity Warrant stock entering bullish territoryBreakout Watch & Capital Efficient Trade Techniques - Newser
Tools to assess Dermata Therapeutics Inc. Equity Warrant’s risk profile2025 Earnings Impact & Step-by-Step Trade Execution Guides - Newser
Will Natural Grocers by Vitamin Cottage Inc. continue its uptrendPrice Action & AI Driven Stock Movement Reports - Newser
Is Dermata Therapeutics Inc. Equity Warrant forming a reversal patternJuly 2025 Highlights & AI Forecast Swing Trade Picks - Newser
How to use a screener to detect Dermata Therapeutics Inc. Equity Warrant breakoutsRate Hike & Safe Swing Trade Setups - Newser
What is Dermata Therapeutics Inc. s revenue forecast2025 Retail Activity & Daily Volume Surge Trade Alerts - mustnews.co.kr
How to forecast Dermata Therapeutics Inc. Equity Warrant trends using time seriesPortfolio Risk Report & Fast Gain Swing Alerts - Newser
Is Dermata Therapeutics Inc. Equity Warrant Stock a Smart Buy in 2025 Investment Analysis Inside - Newser
What the charts say about Dermata Therapeutics Inc. todayMarket Trend Report & Weekly Market Pulse Alerts - Newser
Why Dermata Therapeutics Inc. Equity Warrant stock is on top investor watchlistsEarnings Recap Summary & Short-Term Swing Trade Alerts - Newser
Analyzing recovery setups for Dermata Therapeutics Inc. investorsPortfolio Value Summary & Advanced Swing Trade Entry Alerts - Newser
Using fundamentals and technicals on Dermata Therapeutics Inc.July 2025 Retail & Growth Focused Stock Reports - Newser
Leading vs lagging indicators on Dermata Therapeutics Inc. Equity Warrant performancePortfolio Update Report & Proven Capital Preservation Methods - Newser
Dermata Therapeutics Inc Stock (DRMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):